https://doi.org/10.55788/06698a91
Dr Benjamin Brinkmann (Mayo Clinic, MI, USA) and his consortium investigated various technological approaches to forecast seizures, including wearables, smartphone apps, and minimally-invasive devices [1]. Here, he allowed himself a joke: “Initially, we considered leveraging the popularity of seizure alert dogs in a wearable system, but we quickly discarded this idea out of concerns for chronic shoulder pain, as well as a possible high false-alarm rate due to cats, mail carriers, and tennis balls.” Dr Brinkmann's consortium opted instead to evaluate 2 wearable biosensors, the wrist-worn Empatica E4 and Fitbit Inspire. When discharged from the hospital, study participants received both devices, to use one while charging the other. Participants were given 1 of 3 ambulatory EEG monitoring devices for seizure confirmation: UNEEG, SubQ, or EpiMinder. Wearable and EEG data from enrolled participants were recorded for 8 months or more. Self-reported electronic seizure diaries and periodic mood and symptom surveys were recorded by participants as well.
Of the 39 included participants, only 5 discontinued during follow-up. Over 17,000 days (approx. 46 years) were recorded with over 1,700 seizures. Using the Empatica E4 device for at least 6 months, seizure forecasting was better than chance in 5 of 6 so far studied participants, with a mean AUC (area under the receiver operating characteristics curve) of 0.80. Dr Brinkmann: “On average, we predicted 2/3 of their seizures, with about 30 minutes of pre-seizure warning, and several false alarms.” He added that a data science contest on the open platform https://eval.ai replicated these outcomes. “But we do think more progress is needed to improve performance.” In 5 of 6 patients that could be studied, the sub-scalp EEG signals also independently helped to forecast seizures [2].
Using an additional cohort of 65 app users, Brinkmann's group looked for possible premonitory seizure symptoms in the next 24 hours. “Interestingly, we found a strong relation between impending self-reported seizures and patients' perceived risk as well as recently reported seizures.” Mood, sleep quality, and recent seizures were significantly predictive of seizures. These data are expected and were not yet published at the time of the AAN meeting.
- Brinkmann B. Seizure forecasting and detection with wearable devices and subcutaneous EEG – outcomes from the My Seizure Gauge trial. PL4.001, AAN 2023 Annual Meeting, 22–27 April, Boston, USA.
- Viana PF, et al. Epilepsia, 2022;April 8. DOI: 10.1111/epi.17252.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Encouraging first results of GABAergic interneurons implants for focal epilepsy Next Article
A vaccine as a potentially safe and effective immunotherapy against CGRP »
« Encouraging first results of GABAergic interneurons implants for focal epilepsy Next Article
A vaccine as a potentially safe and effective immunotherapy against CGRP »
Table of Contents: AAN 2023
Featured articles
Letter from the Editor
Positive results for hereditary transthyretin-mediated amyloid polyneuropathy
Infectious Diseases
Allogenic T-cell-based immunotherapy for PML in development
Cognitive Impairment and Dementia
Lecanemab may slow decline of cognition and function in Alzheimer’s Disease
Donanemab shows rapid and deep plaque clearance in early Alzheimer’s Disease
Epilepsy
Seizure forecasting and detection with wearable devices are feasible
Encouraging first results of GABAergic interneurons implants for focal epilepsy
Headache and Migraine
Lecture on migraine: from the prodromal phase to future paradigm shifts
Zavegepant nasal spray exhibits good efficacy and safety in acute migraine
A vaccine as a potentially safe and effective immunotherapy against CGRP
Multiple Sclerosis
Teriflunomide prevents conversion to MS in patients with RIS
Gold nanocrystals may be effective as adjunctive MS therapy
Muscle and Neuro-Muscular Disorders
First-ever ALS platform trial reports on outcomes of 4 treatments
Pridopidine for Huntington’s disease fails to meet the primary endpoint
Parkinson's Disease
Continuous levodopa/carbidopa infusion shows favourable safety and efficacy
Unilateral right STN-DBS improves verbal fluency
Stroke
Harnessing the microbiome as a possible stroke treatment
Patients with a large core infarct benefit from thrombectomy
Miscellaneous
Artificial intelligence applications in neurology: seize the moment
Spinal cord stimulation eases painful diabetic neuropathy
EVT improves functional outcomes in Chinese patients with BAO
Severe sleep apnoea associated with white matter hyperintensities
Related Articles
October 30, 2022
In the spotlight: Cancer trends in obstructive sleep apnoea
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com